Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04469556 · ClinicalTrials.gov registry record · Phase 2
Pancreatic Adenocarcinoma Signature Stratification for Treatment
A Phase 2 study, sponsored by University Health Network, Toronto.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT04469556 is a Phase 2 study that has completed, run by University Health Network, Toronto. The registered enrollment target is 150 participants.
The verdict
NCT04469556, a Phase 2 study, has completed, sponsored by University Health Network, Toronto.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
This is a randomized multicentre phase II trial with a large translational component. The trial will evaluate the two standard chemotherapy regimens: modified folfirinox (mFFX) and gemcitabine/nab-paclitaxel (GA), in patients with untreated metastatic pancreatic ductal adenocarcinoma. Integrated into this phase II trial are a number of laboratory components including molecular profiling, patient derived organoid establishment, and drug testing sensitivity and other biomarkers.
Interventions
- DRUG Folfirinox
- DRUG Gemcitabine/nab-paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-10-14 |
| Est. Completion | 2025-03-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04469556
The ClinicalTrials.gov registry entry for NCT04469556 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Health Network, Toronto, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Folfirinox is the first listed.
NCT04469556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04469556 about?
NCT04469556 is a clinical study titled "Pancreatic Adenocarcinoma Signature Stratification for Treatment". This is a randomized multicentre phase II trial with a large translational component. The trial will evaluate the two standard chemotherapy regimens: modified folfirinox (mFFX) and gemcitabine/nab-paclitaxel (GA), in patients with untreated metastatic pancreatic ductal adenocarcinoma. Integrated int...
What is the current status of trial NCT04469556?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2020-10-14. Estimated completion is 2025-03-05.
What interventions are being tested in trial NCT04469556?
The interventions under investigation include: Folfirinox (DRUG), Gemcitabine/nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT04469556?
This trial is sponsored by University Health Network, Toronto, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.